Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

NCT01176669 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Apatinib

Sponsor

Fudan University

Collaborators

[object Object]